Direkt zum Inhalt
Merck

Fortfahren mit

F6307

FLT1 (784-end), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Synonym(e):

VEGFR1

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis

Über diesen Artikel

NACRES:
NA.32
UNSPSC Code:
51111800
Form:
buffered aqueous glycerol solution
Assay:
≥70% (SDS-PAGE)
Recombinant:
expressed in baculovirus infected Sf9 cells
Mol wt:
~94 kDa
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


recombinant

expressed in baculovirus infected Sf9 cells

Quality Level

product line

PRECISIO® Kinase

assay

≥70% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

30-40 nmol/min·mg

mol wt

~94 kDa

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... FLT1(2321)

General description

FLT1 (fms-related tyrosine kinase 1) or VEGFR (vascular endothelial growth factor receptor) is one of the receptor tyrosine kinase, which acts as a receptor for VEGF. VEGF is a predominant angiogenesis stimulating factor. FLT1 is a transmembrane receptor.[1] Soluble FLT1 (sFLT1) is an alternatively spliced soluble form of FLT1, expressed by multiple tissues. It acts as a negative regulator of VEGF. It does not contain the cytosolic and transmembrane domains.[2]

Biochem/physiol Actions

FLT1 (fms-related tyrosine kinase 1) or VEGFR (vascular endothelial growth factor receptor) is implicated in angiogenesis in tumors, which plays a key role in tumorigenesis, invasion and metastasis of tumors, especially the malignant ones.[1] In human circulation, angiogenesis is balanced by soluble FLT1 (sFLT1) and VEGF. An imbalance leads to multiple conditions such as pre-eclampsia.[2] sFLT1 plays an essential role in the angiogenesis of placenta. An overexpression of this protein in placenta is associated with prenatal arsenic exposure and thus, reduced birth weight.[3]

Physical form

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
SRP5276F6432F7930
assay

≥70% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

assay

≥70% (SDS-PAGE)

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

recombinant

expressed in baculovirus infected Sf9 cells

mol wt

~94 kDa

mol wt

~75 kDa

mol wt

~73 kDa

mol wt

~73 kDa

form

buffered aqueous glycerol solution

form

buffered aqueous glycerol solution

form

buffered aqueous glycerol solution

form

buffered aqueous glycerol solution

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

Gene Information

human ... FLT1(2321)

Gene Information

human ... FGFR1(2260)

Gene Information

human ... FLT3(2322)

Gene Information

human ... FGFR3(2261)


Lagerklasse

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Ya-Ling Zhai et al.
PloS one, 9(7), e101779-e101779 (2014-07-10)
Endothelial injury, which may present clinically as hypertension, proteinuria and increased von Willebrand Factor (vWF) level, is a common manifestation in IgA nephropathy (IgAN). However, causal factors for endothelial injury in IgAN are not completely understood. An imbalance of vascular
Sylvie Remy et al.
PloS one, 9(3), e92677-e92677 (2014-03-26)
There is increasing epidemiologic evidence that arsenic exposure in utero is associated with adverse pregnancy outcomes and may contribute to long-term health effects. These effects may occur at low environmental exposures but the underlying molecular mechanism is not clear. We
Monica Autiero et al.
Nature medicine, 9(7), 936-943 (2003-06-11)
Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase (RTK) Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1



Global Trade Item Number

SKUGTIN
F6307-10UG04061832850160

Questions

Reviews

No rating value

Active Filters